— Know what they know.
Not Investment Advice
Also trades as: 0HIY.L (LSE) · $vol 0M

ATRA Short Interest

Atara Biotherapeutics, Inc.
1W: -9.4% 1M: -0.8% 3M: +3.0% YTD: -53.3% 1Y: -42.7% 3Y: -75.8% 5Y: -97.8%
$8.30
-0.05 (-0.60%)
Pre-Market: $8.67 (+0.37, +4.46%)
Weekly Expected Move ±10.1%
$7 $8 $9 $9 $10
NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 36 · $83.3M mcap · 7M float · 0.796% daily turnover · Short 46% of daily vol
Credit Risk of going bust: higher than 91% of companies Debt: 10.6% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the riskiest tenth, about 1 in 20 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.25 (down 97%), Atara Biotherapeutics, Inc. would be worth roughly what it owes.
Total debt $9.9M against a stock market value of $83.3M.
Distance to default 1.49 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $4.9M (short-term plus half of long-term), stock volatility 142.0%; Altman Z'' -317.91. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Short Volume Summary

2026-10-27
82.1%
Short Ratio
of total volume
45.6%
20-Day Avg
46.0%
50-Day Avg
▲ Rising
5-Day Trend
0.0M
Short Volume
0.0M
Total Volume

Daily Short Volume Ratio

Short Volume vs Total Volume

Exchange Breakdown

2026-10-27
ExchangeShort VolumeTotal VolumeShort %
NASDAQ 1,560 1,906 81.8%
NYSE 154 182 84.6%

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms